A20, tumour necrosis factor alpha-induced protein 3; APOBEC3A/A3A, apolipoprotein B mRNA editing catalytic polypeptide-like A; APOBEC3B; APOBEC3B/A3B, apolipoprotein B mRNA editing catalytic polypeptide-like B; APOBEC3G/A3G, apolipoprotein B mRNA editing catalytic polypeptide-like G; BCA, bicinchoninic acid assay; CHB, chronic hepatitis B; CXCL10, C-X-C motif chemokine ligand 10; ChIP, chromatin immune precipitation; EMSA, electrophoretic mobility-shift assay; H3K4Me3, histone 3 lysine 4 trimethylation; HBx; Hepatitis B virus; IFNα/γ, interferon alpha/gamma; IKKα/ß, IκB kinase alpha/beta; JMJD8, jumonji domain containing 8; LPS, lipopolysaccharide; LTßR, lymphotoxin beta receptor; MAPK, mitogen-activated protein kinase; NEMO, NF-κB essential modulator; NF-κB; NF-κB, nuclear factor kappa B; NIK, NF-κB inducing kinase; NT, non-treated; RT-qPCR, reverse transcription-quantitative PCR; RelA, NF-κB p65 subunit; TNF, tumour necrosis factor; UBE2V1, ubiquitin conjugating enzyme E2 V1; UTR, untranslated region; cccDNA; cccDNA, covalently closed circular DNA; d.p.i., days post infection; miRNA; miRNA, micro RNA; siCTRL, siRNA control